Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial

PLoS Medicine

Volumn 11, Issue 12, 2014, Pages

  Laman, Moses ^a,b   Moore, Brioni R ^a,b   Benjamin, John M ^b   Yadi, Gumul ^b   Bona, Cathy ^b   Warrel, Jonathan ^b   Kattenberg, Johanna H ^b,c   Koleala, Tamarah ^b   Manning, Laurens ^a   Kasian, Bernadine ^b   Robinson, Leanne J ^b,c   Sambale, Naomi ^b   Lorry, Lina ^b   Karl, Stephan ^a,c   Davis, Wendy A ^a   Rosanas Urgell, Anna ^b   Mueller, Ivo ^c,d   Siba, Peter M ^b   Betuela, Inoni ^b   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Centre de Recerca en Salut Internacional de Barcelona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ PLUS NAPHTHOQUINONE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; UNCLASSIFIED DRUG; ARTEMETHER; ARTEMISININ; ARTEMISININ DERIVATIVE; BENFLUMETOL; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FEMALE; FOLLOW UP; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALARIA; MALE; OPEN STUDY; PAPUA NEW GUINEAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADULT; MALARIA, FALCIPARUM; MIDDLE AGED;

ADULT; ANTIMALARIALS; ARTEMISININS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED;

EID: 84920973136     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001773     Document Type: Article

References (48)

1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413–431.
2. Mendis K, Sina BJ, Marchesini P, Carter R, (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97–106.
3. Baird JK, (2008) Real-world therapies and the problem of vivax malaria. N Engl J Med 359: 2601–2603.
4. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79–87.
5. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545–2557.
6. Papua New Guinea National Department of Health (2009) National malaria treatment protocol. Port Moresby: National Department of Health.
7. Manning L, Laman M, Law I, Bona C, Aipit S, et al. (2011) Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS ONE 6: e29203.
8. Wang JY, Cao WC, Shan CQ, Zhang M, Li GF, et al. (2004) Naphthoquine phosphate and its combination with artemisinine. Acta Trop 89: 375–381.
9. Hombhanje FW, Huang Q, (2010) Artemisinin-naphthoquine combination (ARCO®): an overview of the progress. Pharmaceuticals 3: 3581–3593.
10. Batty KT, Salman S, Moore BR, Benjamin J, Lee ST, et al. (2012) Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob Agents Chemother 56: 2472–2484.
11. Benjamin J, Moore B, Lee ST, Senn M, Griffin S, et al. (2012) Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob Agents Chemother 56: 2465–2471.
12. World Health Organization (2010) Guidelines for the treatment of malaria, 2nd edition. Geneva: World Health Organization
13. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF, (2005) Piperaquine: a resurgent antimalarial drug. Drugs 65: 75–87.
14. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, et al. (2011) Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother 55: 4479–4481.
15. World Health Organization (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization.
16. Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, et al. (2014) Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 3: CD006404.
17. European Medicines Agency (2012) Assessment report. Pyramax—pyronaridine tetraphosphate/artesunate. Procedure No.: EMEA/H/W/002319. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129290.pdf. Accessed 19 November 2014.
18. World Health Organization (2000) Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94 (Suppl 1)S1–S90.
19. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, et al. (2004) Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol 57: 93–99.
20. Moore BR, Benjamin JM, Salman S, Griffin S, Ginny E, et al. (2014) Effect of co-administered fat on the tolerability, safety and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 58: 5784–5794.
21. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, et al. (2007) How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 12: 195–200.
22. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of MSP-1, MSP-2, and GLURP. Am J Trop Med Hyg 68: 133–139.
23. Felger I, Beck HP, (2002) Genotyping of Plasmodium falciparum. PCR-RFLP analysis. Methods Mol Med 72: 117–129.
24. Wong RP, Salman S, Ilett KF, Siba PM, Mueller I, et al. (2011) Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother 55: 1194–1198.
25. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, et al. (2011) Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 55: 5306–5313.
26. Manning L, Laman M, Townsend MA, Chubb SP, Siba PM, et al. (2011) Reference intervals for common laboratory tests in Melanesian children. Am J Trop Med Hyg 85: 50–54.
27. Blackwelder WC, (1982) “Proving the null hypothesis” in clinical trials. Control Clin Trials 3: 345–353.
28. Pocock SJ (1983) Clinical trials: a practical approach. Chichester: John Wiley.
29. Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, et al. (2003) Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 34: 316–321.
30. Tjitra E, Hasugian AR, Siswantoro H, Prasetyorini B, Ekowatiningsih R, et al. (2012) Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J 11: 153.
31. Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, et al. (2013) Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J 12: 409.
32. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, et al. (2004) Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57: 253–262.
33. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, et al. (2008) Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother 52: 237–243.
34. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, et al. (2012) Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 56: 3288–3297.
35. Ezzet F, Mull R, Karbwang J, (1998) Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 46: 553–561.
36. WorldWide Antimalarial Resistance Network (WWARN) DP Study Group (2013) The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med 10: e1001564.
37. Hassan Alin M, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A, (1996) Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg 90: 61–65.
38. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ, (1999) Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 12: 151–158.
39. Skinner TS, Manning LS, Johnston WA, Davis TM, (1996) In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol 26: 519–525.
40. Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, et al. (2014) Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. Antimicrob Agents Chemother 58: 432–439.
41. Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, et al. (2010) In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea. Trop Med Int Health 15: 342–349.
42. Kurth F, Belard S, Basra A, Ramharter M, (2011) Pyronaridine-artesunate combination therapy for the treatment of malaria. Curr Opin Infect Dis 24: 564–569.
43. White NJ, (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7: 549–558.
44. Bustos MD, Gay F, Diquet B, Thomare P, Warot D, (1994) The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 45: 83–86.
45. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, et al. (2012) Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56: 1571–1577.
46. Borsini F, Crumb W, Pace S, Ubben D, Wible B, et al. (2012) In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother 56: 3261–3270.
47. Van Dorn CS, Johnson JN, Taggart NW, Thorkelson L, Ackerman MJ, (2011) QTc values among children and adolescents presenting to the emergency department. Pediatrics 128: e1395–1401.
48. European Medicines Agency (2011) Annex I: summary of product characteristics. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf. Accessed 25 November 2014.